tiprankstipranks
Advertisement
Advertisement

BRNS Stock Latest News

Barinthus Biotherapeutics Shareholders Approve Scheme of Arrangement
Company AnnouncementsBarinthus Biotherapeutics Shareholders Approve Scheme of Arrangement
6d ago
8K
BRNS
Analyst Flags High Risk in Barinthus Biotherapeutics’ Forward-Looking Statements and Guidance Reliability
PremiumCompany Announcements
Analyst Flags High Risk in Barinthus Biotherapeutics’ Forward-Looking Statements and Guidance Reliability
26d ago
BRNS
Barinthus’ VTP-300 Hepatitis B Study Reaches Completion: What Investors Should Watch Next
PremiumCompany Announcements
Barinthus’ VTP-300 Hepatitis B Study Reaches Completion: What Investors Should Watch Next
27d ago
BRNS
Barinthus Biotherapeutics appoints Douglas Swirsky as CFO
PremiumCompany Announcements
Barinthus Biotherapeutics appoints Douglas Swirsky as CFO
1M ago
8K
BRNS
Barinthus Biotherapeutics Announces Upcoming Accounting Leadership Change
PremiumCompany Announcements
Barinthus Biotherapeutics Announces Upcoming Accounting Leadership Change
2M ago
8K
BRNS
Barinthus Bio Announces 2025 Results and Clywedog Merger
PremiumCompany AnnouncementsBarinthus Bio Announces 2025 Results and Clywedog Merger
2M ago
8K
BRNS
Barinthus Biotherapeutics reports FY25 EPS ($1.64) vs ($1.55) last year
Premium
The Fly
Barinthus Biotherapeutics reports FY25 EPS ($1.64) vs ($1.55) last year
2M ago
BRNS
Barinthus Biotherapeutics Amends Cross-Border Merger Agreement Terms
Premium
Company Announcements
Barinthus Biotherapeutics Amends Cross-Border Merger Agreement Terms
3M ago
8K
BRNS
Barinthus Biotherapeutics Receives Nasdaq Minimum Bid Price Notice
PremiumCompany Announcements
Barinthus Biotherapeutics Receives Nasdaq Minimum Bid Price Notice
5M ago
8K
BRNS
Promising Clinical Trial Results and Strategic Merger Drive Buy Rating for Barinthus Biotherapeutics
PremiumRatings
Promising Clinical Trial Results and Strategic Merger Drive Buy Rating for Barinthus Biotherapeutics
6M ago
BRNS
Barinthus Biotherapeutics Updates on AVALON Trial Progress
PremiumCompany Announcements
Barinthus Biotherapeutics Updates on AVALON Trial Progress
6M ago
8K
BRNS
Barinthus Biotherapeutics announces update on Phase 1 trial of VTP-1000
PremiumThe Fly
Barinthus Biotherapeutics announces update on Phase 1 trial of VTP-1000
6M ago
BRNS
Buy Rating for Barinthus Biotherapeutics: Promising Clinical Developments and Strategic Merger with Clywedog Therapeutics
PremiumRatingsBuy Rating for Barinthus Biotherapeutics: Promising Clinical Developments and Strategic Merger with Clywedog Therapeutics
6M ago
BRNS
Barinthus Biotherapeutics price target raised to $4 from $3 at H.C. Wainwright
Premium
The Fly
Barinthus Biotherapeutics price target raised to $4 from $3 at H.C. Wainwright
6M ago
BRNS
Barinthus Biotherapeutics Reports Q3 2025 Earnings
Premium
Company Announcements
Barinthus Biotherapeutics Reports Q3 2025 Earnings
7M ago
BRNS
Barinthus Biotherapeutics reports Q3 EPS (36c) vs (21c) last year
PremiumThe Fly
Barinthus Biotherapeutics reports Q3 EPS (36c) vs (21c) last year
7M ago
BRNS
Barinthus Biotherapeutics Advances Celiac Disease Treatment with VTP-1000 Trial
PremiumCompany Announcements
Barinthus Biotherapeutics Advances Celiac Disease Treatment with VTP-1000 Trial
7M ago
BRNS
Barinthus Biotherapeutics Announces Merger with Clywedog Therapeutics
PremiumCompany Announcements
Barinthus Biotherapeutics Announces Merger with Clywedog Therapeutics
8M ago
8K
BRNS
Barinthus Bio, Clywedog enter definitive merger agreement
PremiumThe Fly
Barinthus Bio, Clywedog enter definitive merger agreement
8M ago
BRNS
Barinthus Biotherapeutics: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
PremiumRatingsBarinthus Biotherapeutics: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
10M ago
BRNS
Barinthus Biotherapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Barinthus Biotherapeutics Reports Q2 2025 Financial Results
10M ago
BRNS
Barinthus Biotherapeutics reports Q2 EPS (52c) vs. (49c) last year
Premium
The Fly
Barinthus Biotherapeutics reports Q2 EPS (52c) vs. (49c) last year
10M ago
BRNS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >